CUE News & Events

Cue Biopharma announced that it will deliver a poster presentation on the company's lead asset, CUE-401, at the World Immune Regulation Meeting, WIRM, being held March 11-14, 2026 in Davos, Switzerland. The presentation will include new in vitro data that demonstrate the therapeutic potential of CUE-401 to restore immune balance for the treatment of autoimmune and inflammatory diseases. Title: CUE-401: A Novel Bifunctional TGF-beta/IL-2 Fusion Protein for the Treatment of Autoimmune and Inflammatory Diseases. In CD4+ T effector memory cells, CUE-401 showed TGF-beta-dependent suppression of proinflammatory cytokines, including Th1, Th2, and Th17 responses. In addition, the TGF-beta in CUE-401 prevented activated B cells from differentiating into plasma cells and limited antibody production. In natural killer cells, TGF-beta in CUE-401 counterbalanced the activating effects of interleukin-2, preventing proliferation and upregulation of proinflammatory cytokine production. Together, we believe these results demonstrate that CUE-401 has the potential to provide both short-term control of diverse inflammatory processes via TGF-beta, while also potentially providing durable long-term benefit through the induction and expansion of regulatory T cell responses

Cue Biopharma announced preclinical safety and tolerability data that further supports the preclinical profile of CUE-401, the Company's lead autoimmune asset. "We are very encouraged with this preclinical data, which demonstrated that CUE-401 was well tolerated, and no adverse events were observed," said Usman Azam, M.D., president and chief executive officer of Cue Biopharma. "Data generated from these preclinical studies represent an important addition to the growing evidence supporting the potential of CUE-401 as a first-in-class bifunctional tolerogenic agent for the treatment of autoimmune disease. We look forward to sharing further scientific data and details on the planned investigational new drug (IND) filing for CUE-401 in the upcoming months."

Cue Biopharm announced that Lucinda Warren, who has served as Cue Biopharma's chief business officer, CBO, since September 2024, has been appointed chief financial and business officer, CFBO, effective February 9, 2026.

Cue Biopharma announced the pricing of an underwritten public offering of 35,714,286 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 17,857,143 shares of common stock. Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $0.28. The aggregate gross proceeds of the offering are expected to be approximately $10 million, before deducting underwriting discounts and commissions and other offering expenses. Each common stock warrant will have an exercise price of $0.30 per share, will be exercisable immediately and will expire five years from the date of issuance. The offering is expected to close on or about December 22, 2025, subject to satisfaction of customary closing conditions. In addition, Cue Biopharma has granted the underwriters an option for a period of 30 days to purchase up to an additional 5,357,140 shares of its common stock and/or warrants to purchase up to 2,678,570 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the securities are being offered by Cue Biopharma. H.C. Wainwright & Co. is acting as sole book-running manager for the offering. Newbridge Securities Corporation is acting as co-manager for the offering.